Strategy and planning for chemopreventive drug development

clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute.

G. J. Kelloff, J. A. Crowell, C. W. Boone, V. E. Steele, R. A. Lubet, P. Greenwald, David S Alberts, J. M. Covey, L. A. Doody, G. G. Knapp

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

At the National Cancer Institute, Division of Cancer Prevention and Control, the Chemoprevention Branch and Agent Development Committee develop strategies for efficiently identifying, procuring, and advancing the most promising drugs into clinical trials. Scientific expertise is applied at each phase of development to critically review the testing methods and results, and to establish and apply criteria for evaluating the agents for further development. The Clinical Development Plan, prepared by the Chemoprevention Branch and the Agent Development Committee, is a summary of the status of the agent regarding evidence for safety and chemopreventive efficacy in preclinical and clinical studies. It also contains the strategy for further development of the drug that addresses pharmacodynamics, drug effect measurements, intermediate biomarkers for monitoring efficacy, toxicity, supply and formulation, regulatory approval, and proposed clinical trials. Sixteen Clinical Development Plans are presented here: N-acetyl-l-cysteine (NAC), aspirin, calcium, beta-carotene, 2-difluoromethylornithine (DFMO), DHEA analog 8354, 18 beta-glycyrrhetinic acid, N-(4-hydroxyphenyl)retinamide (4-HPR), ibuprofen, oltipraz, piroxicam, Proscar, sulindac, tamoxifen, vitamin D3 and analogs, and vitamin E. The objective of publishing these plans is to stimulate interest and thinking among the scientific community on the prospects for developing chemopreventive drugs.

Original languageEnglish (US)
Pages (from-to)55-62
Number of pages8
JournalJournal of cellular biochemistry. Supplement
Volume20
StatePublished - 1994
Externally publishedYes

Fingerprint

National Cancer Institute (U.S.)
Chemoprevention
Pharmaceutical Preparations
Fenretinide
Clinical Trials
Glycyrrhetinic Acid
Sulindac
Finasteride
Eflornithine
Piroxicam
Cholecalciferol
Ibuprofen
beta Carotene
Tamoxifen
Vitamin E
Aspirin
Cysteine
Biomarkers
Calcium
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Strategy and planning for chemopreventive drug development : clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute. / Kelloff, G. J.; Crowell, J. A.; Boone, C. W.; Steele, V. E.; Lubet, R. A.; Greenwald, P.; Alberts, David S; Covey, J. M.; Doody, L. A.; Knapp, G. G.

In: Journal of cellular biochemistry. Supplement, Vol. 20, 1994, p. 55-62.

Research output: Contribution to journalArticle

Kelloff, G. J. ; Crowell, J. A. ; Boone, C. W. ; Steele, V. E. ; Lubet, R. A. ; Greenwald, P. ; Alberts, David S ; Covey, J. M. ; Doody, L. A. ; Knapp, G. G. / Strategy and planning for chemopreventive drug development : clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute. In: Journal of cellular biochemistry. Supplement. 1994 ; Vol. 20. pp. 55-62.
@article{44d9b3bf4dc246a79ca6cb1c1df15b58,
title = "Strategy and planning for chemopreventive drug development: clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute.",
abstract = "At the National Cancer Institute, Division of Cancer Prevention and Control, the Chemoprevention Branch and Agent Development Committee develop strategies for efficiently identifying, procuring, and advancing the most promising drugs into clinical trials. Scientific expertise is applied at each phase of development to critically review the testing methods and results, and to establish and apply criteria for evaluating the agents for further development. The Clinical Development Plan, prepared by the Chemoprevention Branch and the Agent Development Committee, is a summary of the status of the agent regarding evidence for safety and chemopreventive efficacy in preclinical and clinical studies. It also contains the strategy for further development of the drug that addresses pharmacodynamics, drug effect measurements, intermediate biomarkers for monitoring efficacy, toxicity, supply and formulation, regulatory approval, and proposed clinical trials. Sixteen Clinical Development Plans are presented here: N-acetyl-l-cysteine (NAC), aspirin, calcium, beta-carotene, 2-difluoromethylornithine (DFMO), DHEA analog 8354, 18 beta-glycyrrhetinic acid, N-(4-hydroxyphenyl)retinamide (4-HPR), ibuprofen, oltipraz, piroxicam, Proscar, sulindac, tamoxifen, vitamin D3 and analogs, and vitamin E. The objective of publishing these plans is to stimulate interest and thinking among the scientific community on the prospects for developing chemopreventive drugs.",
author = "Kelloff, {G. J.} and Crowell, {J. A.} and Boone, {C. W.} and Steele, {V. E.} and Lubet, {R. A.} and P. Greenwald and Alberts, {David S} and Covey, {J. M.} and Doody, {L. A.} and Knapp, {G. G.}",
year = "1994",
language = "English (US)",
volume = "20",
pages = "55--62",
journal = "Journal of cellular biochemistry. Supplement",
issn = "0733-1959",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Strategy and planning for chemopreventive drug development

T2 - clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute.

AU - Kelloff, G. J.

AU - Crowell, J. A.

AU - Boone, C. W.

AU - Steele, V. E.

AU - Lubet, R. A.

AU - Greenwald, P.

AU - Alberts, David S

AU - Covey, J. M.

AU - Doody, L. A.

AU - Knapp, G. G.

PY - 1994

Y1 - 1994

N2 - At the National Cancer Institute, Division of Cancer Prevention and Control, the Chemoprevention Branch and Agent Development Committee develop strategies for efficiently identifying, procuring, and advancing the most promising drugs into clinical trials. Scientific expertise is applied at each phase of development to critically review the testing methods and results, and to establish and apply criteria for evaluating the agents for further development. The Clinical Development Plan, prepared by the Chemoprevention Branch and the Agent Development Committee, is a summary of the status of the agent regarding evidence for safety and chemopreventive efficacy in preclinical and clinical studies. It also contains the strategy for further development of the drug that addresses pharmacodynamics, drug effect measurements, intermediate biomarkers for monitoring efficacy, toxicity, supply and formulation, regulatory approval, and proposed clinical trials. Sixteen Clinical Development Plans are presented here: N-acetyl-l-cysteine (NAC), aspirin, calcium, beta-carotene, 2-difluoromethylornithine (DFMO), DHEA analog 8354, 18 beta-glycyrrhetinic acid, N-(4-hydroxyphenyl)retinamide (4-HPR), ibuprofen, oltipraz, piroxicam, Proscar, sulindac, tamoxifen, vitamin D3 and analogs, and vitamin E. The objective of publishing these plans is to stimulate interest and thinking among the scientific community on the prospects for developing chemopreventive drugs.

AB - At the National Cancer Institute, Division of Cancer Prevention and Control, the Chemoprevention Branch and Agent Development Committee develop strategies for efficiently identifying, procuring, and advancing the most promising drugs into clinical trials. Scientific expertise is applied at each phase of development to critically review the testing methods and results, and to establish and apply criteria for evaluating the agents for further development. The Clinical Development Plan, prepared by the Chemoprevention Branch and the Agent Development Committee, is a summary of the status of the agent regarding evidence for safety and chemopreventive efficacy in preclinical and clinical studies. It also contains the strategy for further development of the drug that addresses pharmacodynamics, drug effect measurements, intermediate biomarkers for monitoring efficacy, toxicity, supply and formulation, regulatory approval, and proposed clinical trials. Sixteen Clinical Development Plans are presented here: N-acetyl-l-cysteine (NAC), aspirin, calcium, beta-carotene, 2-difluoromethylornithine (DFMO), DHEA analog 8354, 18 beta-glycyrrhetinic acid, N-(4-hydroxyphenyl)retinamide (4-HPR), ibuprofen, oltipraz, piroxicam, Proscar, sulindac, tamoxifen, vitamin D3 and analogs, and vitamin E. The objective of publishing these plans is to stimulate interest and thinking among the scientific community on the prospects for developing chemopreventive drugs.

UR - http://www.scopus.com/inward/record.url?scp=0028701027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028701027&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 55

EP - 62

JO - Journal of cellular biochemistry. Supplement

JF - Journal of cellular biochemistry. Supplement

SN - 0733-1959

ER -